Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of KSI-301 versus aflibercept for macular edema secondary to retinal vein occlusion
ChiCTR2100053499Phase 3Suspended
- Sponsor
- Kodiak Sciences
- Start
- Mar 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tarcocimab tedromer and aflibercept in Vein occlusion (RVO) and macular edema (2 arms), sponsored by Kodiak Sciences. Primary endpoint: Mean change in best corrected visual acuity. Started Mar 2021; status: suspended.
02
Drugs
tarcocimab tedromeraflibercept
03
Conditions
Vein occlusion (RVO)macular edema
Beyond the preview
Go deeper on ChiCTR2100053499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053499.